• 1
    Shishodia S, Aggarwal BB. Nuclear factor-κB activation: a question of life and death. J Biochem Mol Biol 2002; 35: 2840.
  • 2
    Shishodia S, Majumdar S, Banerjee S, Aggarwal BB. Ursolic acid inhibits nuclear factor-κB activation induced by carcinogenic agents through suppression of IκBα kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res 2003; 63: 437583.
  • 3
    Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 685366.
  • 4
    Waddick KG, Uckun FM. Innovative treatment programs against cancer. II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. Biochem Pharmacol 1999; 57: 917.
  • 5
    Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-κB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000; 60: 442632.
  • 6
    Kim SB, Kim JS, Lee JH, Yoon WJ, Lee DS, Ko MS, Kwon BS, Choi DH, Cho HR, Lee BJ, Chung DK, Lee HW, et al. NF-κB activation is required for cisplatin-induced apoptosis in head and neck squamous carcinoma cells. FEBS Lett 2006; 580: 31118.
  • 7
    Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM, Giaccone G. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000; 6: 20312.
  • 8
    Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B. Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis. Clin Cancer Res 1997; 3: 96372.
  • 9
    Costa-Pereira AP, Cotter TG. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer 1999; 80: 3718.
  • 10
    Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 48190.
  • 11
    Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491501.
  • 12
    Mandal M, Adam L, Kumar R. Redistribution of activated caspase-3 to the nucleus during butyric acid-induced apoptosis. Biochem Biophys Res Commun 1999; 260: 77580.
  • 13
    Fields S, Song O. A novel geneic system to detect protein-protein interactions. Nature 1989; 340: 2456.
  • 14
    Pollok BA, Heim R. Using GFP in FRET-based applications. Trends Cell Biol 1999; 9: 5760.
  • 15
    Gaits F, Hahn K. Shedding light on cell signaling: interpretation of FRET biosensors. Sci STKE 2003; 3: 15.
  • 16
    Takemoto K, Nagai T, Miyawaki A, Miura M. Spatiotemporal activation of caspase revealed by indicator that is insensitive to environmental effects. J Cell Biol 2003; 160: 23543.
  • 17
    Onuki R, Nagasaki A, Kawasaki H, Baba T, Uyeda TQ, Taira K. Confirmation by FRET in individual living cells of the absence of significant amyloid β-mediated caspase 8 activation. Proc Natl Acad Sci USA 2002; 99: 1471621.
  • 18
    Kunkel MT, Ni Q, Tsien RY, Zhang J, Newton AC. Spatio-temporal dynamics of protein kinase B/Akt signaling revealed by a genetically encoded fluorescent reporter. J Biol Chem 2005; 280: 55817.
  • 19
    Wu Y, Xing D, Luo S, Tang Y, Chen Q. Detection of caspase-3 activation in single cells by fluorescence resonance energy transfer during photodynamic therapy induced apoptosis. Cancer Lett 2006; 235: 23947.
  • 20
    Li Y, Xing D, Chen Q. Dynamic monitoring of apoptosis in chemotherapy with multiple fluorescence reporters. Mol Imaging Biol 2009; 11: 21322.
  • 21
    Li X, Xing D, Wang J, Zhu D, Zhang L, Chen X, Sun F, Hong A. Effects of IκBα and its mutants on NF-κB and p53 signaling pathways. World J Gastroenterol 2006; 12: 665864.
  • 22
    Nelson G, Paraoan L, Spiller DG, Wilde GJ, Browne MA, Djali PK, Unitt JF, Sullivan E, Floettmann E, White MR. Multi-parameter analysis of the kinetics of NF-kB signalling and transcription in single living cells. J Cell Sci 2002; 115: 113748.
  • 23
    Duffey DC, Crowl-Bancroft CV, Chen Z, Ondrey FG, Nejad-Sattari M, Dong G, Van Waes C. Inhibition of transcription factor nuclear factor-kappaB by a mutant inhibitor-kappaBalpha attenuates resistance of human head and neck squamous cell carcinoma to TNF-alpha caspase-mediated cell death. Br J Cancer 2000; 83: 136774.
  • 24
    Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U, Van Waes C. Expression of a dominant-negative mutant inhibitor-kappa B alpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59: 346874.
  • 25
    Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. Sensitization of Taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase akt and is independent of tubulinpolymerization. J Biol Chem 2005; 280: 63018.
  • 26
    Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D. Biological and chemical inhibitors of NF-kB sensitize SiHa Cells to cisplatin-induced apoptosis. Mol Carcinog 2005; 44: 519.
  • 27
    Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397421.
  • 28
    Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, Khuri FR, Yang CS, Chen ZG, Shin DM. Synergistic inhibition of head and neck tumor growth by green tea (−)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 2008; 123: 100514.
  • 29
    Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D. A phase I trial of Taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9: 12617.
  • 30
    Gosland MP, Goodin S, Yokel RA, Smith M, John WJ. A phase I trial of 5-day continuous infusion cisplatin and interferon alpha. Cancer Chemother Pharmacol 1995; 37: 3946.
  • 31
    Hsu YL, Kuo PL, Lin CC. Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci 2004; 75: 230316.
  • 32
    Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, Guha S, Sethi G, Aggarwal BB. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 2007; 5: 94355.
  • 33
    Lauthier F, Taillet L, Trouillas P, Delage C, Simon A. Ursolic acid triggers calcium-dependent apoptosis in human Daudi cells. Anticancer Drugs 2000; 11: 73745.
  • 34
    Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 2002; 277: 3428794.
  • 35
    Choi YH, Baek JH, Yoo MA, Chung HY, Kim ND, Kim KW. Induction of apoptosis by ursolic acid through activation of caspases and downregulation of c-IAPs in human prostate epithelial cells. Int J Oncol 2000; 17: 56571.
  • 36
    Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kB in cell growth regulation. Am J Pathol 2001; 159: 38797.
  • 37
    Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 160521.
  • 38
    Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K. Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Genes Cells 2005; 10: 105163.
  • 39
    Lee I, Lee J, Lee YH, Leonard J. Ursolic acid-induced changes in tumor growth. O2 consumption, and tumor interstitial fluid pressure. Anticancer Res 2001; 21: 282733.
  • 40
    Pozo M, Castilla V, Gutierrez C, de Nicolás R, Egido J, González-Cabrero J. Ursolic acid inhibits neointima formation in the rat carotid artery injury model. Atherosclerosis 2006; 184: 5362.
  • 41
    Chen W, Xiong X, Wang X. Chemistry, pharmacology and clinical application of ursolic acid. Chin Tradit Pat Med 2002; 24: 70911.
  • 42
    Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 1995; 49: 5768.
  • 43
    Ikeda Y, Murakami A, Ohigashi H. Ursolic acid: an anti- and pro-inflammatory triterpenoid. Mol Nutr Food Res 2008; 52: 2642.